Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — Q2 FY2026 Earnings Presentation
26 slides from Asarfi Hospital's earnings presentation, Nov 10, 2025
Slide 1: Asarfi Hospital Limited
असफ हॉ ीटल सबके िलए ा AHL/AO/2025/1029 Date: 10.11.2025 To The Listing Department BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Sub: Investor Presentation for Q2 & H1 FY 2025–26 Ref: Scrip Code – 543943 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing
Slide 2: Investor Presentation Q2 & H1'FY26
“Leading Healthcare Provider in Eastern India” Investor Presentation Q2 & H1’FY26 1
Slide 3: Agenda
1 Company Overview Agenda 2 Competitive Strengths 3 Vision 2027 & Growth Strategy 4 Leadership Team 5 Financial & Operational Performance 2
Slide 4: Asarfi Hospital: At a Glance
Asarfi Hospital: At a Glance Healthcare Excellence Since 2005 ▪ Serving Dhanbad and neighboring areas for 20 years with affordable, best-in-class healthcare facilities. Operating two hospitals with 330 total beds across Super-Specialty and Cancer Care Units. ▪ The Super-Specialty hospital is the fir
Slide 5: Journey Over The Years
Journey Over The Years 2005 2008 2016 2017 2022 2023 2024 2025 Incorporation IPD Dept Expansion Expansion Cancer hospital IPO Cancer hospital Strategic Phase 1 Phase 2 construction operationalised partnership 2005-2009: Foundation 2016-2022: Expansion 2023-2025: Cancer Hospital, IPO and Partnerships
Slide 6: Our Departments
Our Departments Paediatrics & Obstetrics & Cardiology Neurosciences General medicine General Surgery Neonatology Gynaecology Gastroenterology Orthopaedics Burn & Plastic Surgery Oncology Nephrology Urology Ophthalmology ENT Day Care Dental Sciences Physiotherapy Emergency services Nutrition & Dietet
Slide 7: Infrastructure and Facilities
Infrastructure and Facilities Asarfi Hospital, Dhanbad Asarfi Cancer Institute, Dhanbad Varian True Beam 265 Beds | ₹20,247 ARPOB | 65 Beds | ₹50,614 ARPOB | Jharkhand’s 1st & Most 64% Occupancy | ALOS 3.8 Days 46% Occupancy | ALOS 7 Days Advanced Radiation Machine ▪ Established in 2005 ▪ Establishe
Slide 8: Competitive Strengths
Competitive Strengths 30 Lakh+ 1 out of 3 95+ Advanced Technology Population Served Cancer Hospital Medical Jharkhand’s 1st and most in Jharkhand Professionals advanced radiation machine Regional Advantage Technology Leadership Financial and ▪ Only cancer hospital in ▪ Equipped with Jharkhand’s firs
Slide 9: Vision 2027 and Growth Strategy
Vision 2027 and Growth Strategy Vision 2027: 500 ₹ 200 Cr 25-27% 13-15% Beds Revenues EBITDA Margin PAT Margin Growth Strategy: Capacity Expansion and Consolidation New Verticals & Partnerships Education Business ➢ Increasing bed capacity in the Super- ➢ Establishing a Bone Marrow Transplant ➢ Healt
Slide 10: Leadership Team
Leadership Team Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter & CFO Promoter & MD Non-Executive Director • A visionary entrepreneur inspired by • Started his career in 2017, he is a • Renowned Consultant Gynaecologist the Company’s Purpose—Health for All. process and system driven pers
Slide 11: Uniquely Positioned Healthcare Player
Uniquely Positioned Healthcare Player Market Leadership Strong Financials ✓ Dominant position in Dhanbad region, serving 30+ ✓ 23% Revenue CAGR from FY22-25 lakh people ✓ 43% YoY Revenue Growth in FY25 ✓ One of the largest super-specialty healthcare ✓ 14% ROCE as of FY25 providers in Dhanbad region
Slide 12: Financial and Operational Performance
Financial and Operational Performance 11
Slide 13: Key Highlights
Key Highlights Financials (Standalone): IPD-OPD Revenues (₹ in lakhs): Revenue Growth YoY EBITDA Margin 8,000 50% 20% 7,000 6,770 to ₹81 Cr in H1’FY26 in H1’FY26 6,000 (vs ₹54 Cr in H1’FY25) (vs 22% in H1’FY25) 5,000 4,268 4,000 3,000 EBIT Margin PAT Margin 2,000 1,059 1,159 15% 9% 1,000 in H1’FY26
Slide 14: Key Highlights – Strategic Partnership
Key Highlights – Strategic Partnership 1st ever Multi-Organ Transplant Unit ▪ In partnership with Gleneagles Chennai, Asarfi Hospital is bringing World-class Jharkhand’s first-ever Multi-Organ Transplant Unit. In Jharkhand Transplant Services ▪ Facility to provide world-class transplant services for
Slide 15: Financial Highlights - Standalone
Financial Highlights - Standalone Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % 8,000 2,000 22% 20% 1,600 22% 6,000 20% 20% 1,200 4,000 800 3,086 3,566 4,485 5,378 8,051 1,162 1,594 2,000 680 703 891 400 - - Q2'FY25 Q1'FY26 Q2'FY26 H1'FY25 H1'FY26 Q2'FY25 Q1'FY26 Q2'FY26 H1'FY25 H1'FY26 EBIT
Slide 16: Financial Highlights - Consolidated
Financial Highlights - Consolidated Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % 8,000 2,000 21% 20% 1,600 22% 6,000 20% 20% 1,200 4,000 800 3,086 3,568 4,489 5,378 8,057 1,152 1,586 2,000 400 676 699 887 - - Q2'FY25 Q1'FY26 Q2'FY26 H1'FY25 H1'FY26 Q2'FY25 Q1'FY26 Q2'FY26 H1'FY25 H1'FY26 EB
Slide 17: Revenue Mix – H1'FY25 vs H1'FY26
Revenue Mix – H1’FY25 vs H1’FY26 Super-Specialty Hospital Unit Cardiology Cardiology General Medicine General Medicine 12% 14% 3% 27% Neurosciences 28% Neurosciences 5% 4% General Surgery General Surgery 5% 5% Paediatrics and H1’FY26 Paediatrics and H1’FY25 Neonatology Neonatology 7% 7% Orthopaedics
Slide 18: Revenue Mix – H1'FY25 vs H1'FY26
Revenue Mix – H1’FY25 vs H1’FY26 Cancer Hospital Unit 12% 12% Medical Oncology Medical Oncology 18% Surgical Oncology 21% Surgical Oncology H1’FY25 H1’FY26 54% 57% Radiation Oncology Radiation Oncology 11% 15% Others* Others* *Others Include: Head and Neck oncology, Haemato-oncology and Nuclear Medi
Slide 19: IPD-OPD Highlights (Both Hospital Units)
IPD-OPD Highlights (Both Hospital Units) IPD-OPD Volumes IPD-OPD Revenues (₹ in Lakhs) 80,000 8,000 72,317 70,000 7,000 6,770 60,000 6,000 54,313 50,000 5,000 4,268 39,331 3,773 40,000 4,000 32,986 30,488 2,997 30,000 3,000 2,421 20,000 2,000 12,361 1,159 1,059 10,000 8,414 1,000 5,979 665 522 637 3
Slide 20: Super-Specialty Hospital Unit
Unit-wise ARPOB, Bed Capacity and Occupancy % Super-Specialty Hospital Unit ARPOB Bed Capacity and Occupancy % 19,398 20,247 19,839 17,768 64% 64% 64% 20,000 16,925 61% 59% 300 15,000 200 10,000 Key factors contributing to the 100 250 250 265 250 265 5,000 increase in ARPOB across both 0 0 the hospi
Slide 21: Surgery Count
Surgery Count 4000 Surgery Count 3500 116 134 123 3000 149 232 2500 103 83 348 70 86 178 355 2000 62 268 52 60 54 81 67 304 1500 46 35 144 82 961 102 40 56 190 88 68 166 158 201 570 1000 182 154 434 546 415 500 901 962 488 474 488 0 Q2'FY25 Q1'FY26 Q2'FY26 H1'FY25 H1'FY26 Cardiac Gastro Gen. Surgery
Slide 22: Profit and Loss Account (Standalone)
Profit and Loss Account (Standalone) (₹ in Lakhs) Particulars Q2'FY25 Q1'FY26 Q2'FY26 QoQ % YoY% H1'FY25 H1'FY26 YoY% Revenue from operations 3,086 3,566 4,485 26% 45% 5,378 8,051 50% Material costs (734) (857) (1,059) 24% 44% (1,318) (1,917) 45% Employee benefit expenses (428) (578) (610) 5% 42% (8
Slide 23: Profit and Loss Account (Consolidated)
Profit and Loss Account (Consolidated) (₹ in Lakhs) Particulars Q2'FY25 Q1'FY26 Q2'FY26 QoQ % YoY% H1'FY25 H1'FY26 YoY% Revenue from operations 3,086 3,568 4,489 26% 45% 5,378 8,057 50% Material costs (734) (857) (1,059) 24% 44% (1,318) (1,917) 45% Employee benefit expenses (428) (580) (612) 6% 43%
Slide 24: Balance Sheet (Standalone)
Balance Sheet (Standalone) (₹ in Lakhs) Equity and Liabilities H1'FY25 H1'FY26 Assets H1'FY25 H1'FY26 I. EQUITY III. Assets 1. Shareholder's funds 1. Non-current assets (a) Share capital 1,968 1,968 (a) Property, plant and equipment 8,984 10,179 (b) Reserves and surplus 5,502 6,926 (b) Non-current i
Slide 25: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) (₹ in Lakhs) Equity and Liabilities H1'FY25 H1'FY26 Assets H1'FY25 H1'FY26 I. EQUITY III. Assets 1. Shareholder's funds 1. Non-current assets (a) Share capital 1,968 1,968 (a) Property, plant and equipment 8,991 10,192 (b) Reserves and surplus 5,484 6,862 (b) Non-current
Slide 26: Disclosure and Contact Details
Disclosure and Contact Details Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performanc